Abstract
Hepatocellular carcinoma (HCC) is one of the most common malignancies and a leading cause of cancer-related death worldwide. Surgery remains the primary and most successful therapy option for the treatment of early- and mid-stage HCCs, but the high heterogeneity of HCC renders prognostic prediction challenging. The construction of relevant prognostic models helps to stratify the prognosis of surgically treated patients and guide personalized clinical decision-making, thereby improving patient survival rates. Currently, the prognostic assessment of HCC is based on several commonly used staging systems, such as Tumor-Node-Metastasis (TNM), Cancer of the Liver Italian Program (CLIP), and Barcelona Clinic Liver Cancer (BCLC). Given the insufficiency of these staging systems and the aim to improve the accuracy of prognostic prediction, researchers have incorporated further prognostic factors, such as microvascular infiltration, and proposed some new prognostic models for HCC. To provide insights into the prospects of clinical oncology research, this review describes the commonly used HCC staging systems and new models proposed in recent years.
概要
肝细胞癌(HCC)是全球最常见的恶性肿瘤之一,同时也是癌症相关死亡的主要原因之一。对于肝癌,尤其是早期和中期肝癌,外科手术是首选同时也是最有效的治疗方法。但HCC的高度异质性,给其患者的预后带来了巨大的挑战。预后模型的构建将有助于对手术治疗患者进行预后分层,并指导临床医生采取个体化治疗,从而提高患者的生存率。目前,HCC的预后评估主要基于几种常用的HCC分期系统(如TNM分期、意大利肝癌计划评分(CLIP)和巴塞罗那分期(BCLC))。然而,鉴于这些分期系统存在的不足,也为了提高预后预测的准确性,研究人员进一步纳入患者的其他预后因素,如微血管浸润,并提出了一些新的预后模型。本综述就当前常见的肝癌临床分期系统及近年提出的新预后模型进行阐述,以期为今后的临床研究提供思路。
Similar content being viewed by others
References
Adhoute X, Penaranda G, Bronowicki JP, et al., 2015. Usefulness of the HKLC vs. the BCLC staging system in a European HCC cohort. J Hepatol, 62(2):492–493. https://doi.org/10.1016/j.jhep.2014.08.035
Agopian VG, Harlander-Locke M, Zarrinpar A, et al., 2015. A novel prognostic nomogram accurately predicts hepatocellular carcinoma recurrence after liver transplantation: analysis of 865 consecutive liver transplant recipients. J Am Coll Surg, 220(4):416–427. https://doi.org/10.1016/j.jamcollsurg.2014.12.025
Amin MB, Greene FL, Edge SB, et al., 2017. The Eighth Edition AJCC Cancer Staging Manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin, 67(2):93–99. https://doi.org/10.3322/caac.21388
Balachandran VP, Gonen M, Smith JJ, et al., 2015. Nomograms in oncology: more than meets the eye. Lancet Oncol, 16(4):e173–e180. https://doi.org/10.1016/S1470-2045(14)71116-7
Bolondi L, Burroughs A, Dufour JF, et al., 2012. Heterogeneity of patients with intermediate (BCLC B) hepatocellular carcinoma: proposal for a subclassification to facilitate treatment decisions. Semin Liver Dis, 32(4):348–359. https://doi.org/10.1055/s-0032-1329906
Borzio M, Dionigi E, Rossini A, et al., 2018. External validation of the ITA. LI. CA prognostic system for patients with hepatocellular carcinoma: a multicenter cohort study. Hepatology, 67(6):2215–2225. https://doi.org/10.1002/hep.29662
Bray F, Ferlay J, Soerjomataram I, et al., 2018. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 68(6):394–424. https://doi.org/10.3322/caac.21492
The Cancer of the Liver Italian Program (CLIP) investigators, 1998. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients. Hepatology, 28(3):751–755. https://doi.org/10.1002/hep.510280322
The Cancer of the Liver Italian Program (CLIP) investigators, 2000. Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. Hepatology, 31(4):840–845. https://doi.org/10.1053/he.2000.5628
Chan ACY, Fan ST, Poon RTP, et al., 2013. Evaluation of the seventh edition of the American Joint Committee on Cancer tumour-node-metastasis (TNM) staging system for patients undergoing curative resection of hepatocellular carcinoma: implications for the development of a refined staging system. HPB (Oxford), 15(6):439–448. https://doi.org/10.1111/j.1477-2574.2012.00617.x
Chan AWH, Chong CCN, Mo FKF, et al., 2016. Applicability of albumin-bilirubin-based Japan integrated staging score in hepatitis B-associated hepatocellular carcinoma. J Gastroenterol Hepatol, 31(10):1766–1772. https://doi.org/10.1111/jgh.13339
Chan AWH, Zhong JH, Berhane S, et al., 2018. Development of pre- and post-operative models to predict early recurrence of hepatocellular carcinoma after surgical resection. J Hepatol, 69(6):1284–1293. https://doi.org/10.1016/j.jhep.2018.08.027
Chan SL, Mo FKF, Johnson PJ, et al., 2011. Prospective validation of the Chinese University Prognostic Index and comparison with other staging systems for hepatocellular carcinoma in an Asian population. J Gastroenterol Hepatol, 26(2):340–347. https://doi.org/10.1111/j.1440-1746.2010.06329.x
Chan SL, Johnson PJ, Mo F, et al., 2014. International validation of the Chinese University Prognostic Index for staging of hepatocellular carcinoma: a joint United Kingdom and Hong Kong study. Chin J Cancer, 33(10):481–491. https://doi.org/10.5732/cjc.014.10133
Chen LJ, Chang YJ, Chang YJ, 2021. Survival predictability between the American Joint Committee on Cancer 8th edition staging system and the Barcelona Clinic Liver Cancer classification in patients with hepatocellular carcinoma. Oncologist, 26(3):e445–e453. https://doi.org/10.1002/onco.13535
Chen WQ, Zheng RS, Baade PD, et al., 2016. Cancer statistics in China, 2015. CA Cancer J Clin, 66(2): 115–132. https://doi.org/10.3322/caac.21338
Chun YS, Pawlik TM, Vauthey JN, 2018. 8th Edition of the AJCC Cancer Staging Manual: pancreas and hepatobiliary cancers. Ann Surg Oncol, 25(4):845–847. https://doi.org/10.1245/s10434-017-6025-x
Cong WM, Bu H, Chen J, et al., 2016. Practice guidelines for the pathological diagnosis of primary liver cancer: 2015 update. World J Gastroenterol, 22(42):9279–9287. https://doi.org/10.3748/wjg.v22.i42.9279
di Sandro S, Centonze L, Pinotti E, et al., 2019. Surgical and oncological outcomes of hepatic resection for BCLC-B hepatocellular carcinoma: a retrospective multicenter analysis among 474 consecutive cases. Updates Surg, 71(2):285–293. https://doi.org/10.1007/s13304-019-00649-w
European Association for the Study of the Liver, 2018. EASL Clinical Practice Guidelines: management of hepatocellular carcinoma. J Hepatol, 69(1): 182–236. https://doi.org/10.1016/j.jhep.2018.03.019
Farinati F, Vitale A, Spolverato G, et al., 2016. Development and validation of a new prognostic system for patients with hepatocellular carcinoma. PLoS Med, 13(4):e1002006. https://doi.org/10.1371/journal.pmed.1002006
Filgueira NA, 2019. Hepatocellular carcinoma recurrence after liver transplantation: risk factors, screening and clinical presentation. World J Hepatol, 11(3):261–272. https://doi.org/10.4254/wjh.v11.i3.261
Forner A, Reig M, Bruix J, 2018. Hepatocellular carcinoma. Lancet, 391(10127):1301–1314. https://doi.org/10.1016/S0140-6736(18)30010-2
Giannini EG, Moscatelli A, Pellegatta G, et al., 2016. Application of the intermediate-stage subclassification to patients with untreated hepatocellular carcinoma. Am J Gastroenterol, 111(1):70–77. https://doi.org/10.1038/ajg.2015.389
Giannini EG, Bucci L, Garuti F, et al., 2018. Patients with advanced hepatocellular carcinoma need a personalized management: a lesson from clinical practice. Hepatology, 67(5):1784–1796. https://doi.org/10.1002/hep.29668
Grandhi MS, Kim AK, Ronnekleiv-Kelly SM, et al., 2016. Hepatocellular carcinoma: from diagnosis to treatment. Surg Oncol, 25(2):74–85. https://doi.org/10.1016/j.suronc.2016.03.002
Halazun KJ, Hardy MA, Rana AA, et al., 2009. Negative impact of neutrophil-lymphocyte ratio on outcome after liver transplantation for hepatocellular carcinoma. Ann Surg, 250(1):141–151. https://doi.org/10.1097/SLA.0b013e3181a77e59
Halazun KJ, Najjar M, Abdelmessih RM, et al., 2017. Recurrence after liver transplantation for hepatocellular carcinoma: a new MORAL to the story. Ann Surg, 265(3):557–564. https://doi.org/10.1097/SLA.0000000000001966
He W, Peng BG, Tang YQ, et al., 2018. Nomogram to predict survival of patients with recurrence of hepatocellular carcinoma after surgery. Clin Gastroenterol Hepatol, 16(5): 756–764.e10. https://doi.org/10.1016/j.cgh.2017.12.002
Hou YF, Wei YG, Yang JY, et al., 2016. Combined hepatectomy and radiofrequency ablation versus TACE in improving survival of patients with unresectable BCLC stage B HCC. Hepatobiliary Pancreat Dis Int, 15(4):378–385. https://doi.org/10.1016/S1499-3872(16)60089-9
Huo RR, Liu X, Cui J, et al., 2020. Development and validation of a nomogram for assessing survival in patients with hepatocellular carcinoma after hepatectomy. Biosci Rep, 40(6):BSR20192690. https://doi.org/10.1042/BSR20192690
Jun CH, Yoon JH, Cho E, et al., 2017. Barcelona clinic liver cancer-stage C hepatocellular carcinoma: a novel approach to subclassification and treatment. Medicine (Baltimore), 96(17):e6745. https://doi.org/10.1097/MD.0000000000006745
Kamarajah SK, Frankel TL, Sonnenday C, et al., 2018. Critical evaluation of the American Joint Commission on Cancer (AJCC) 8th edition staging system for patients with Hepatocellular Carcinoma (HCC): a Surveillance, Epidemiology, End Results (SEER) analysis. J Surg Oncol, 117(4): 644–650. https://doi.org/10.1002/jso.24908
Kim JH, Shim JH, Lee HC, et al., 2017. New intermediate-stage subclassification for patients with hepatocellular carcinoma treated with transarterial chemoembolization. Liver Int, 37(12): 1861–1868. https://doi.org/10.1111/liv.13487
Kolly P, Reeves H, Sangro B, et al., 2016. Assessment of the Hong Kong Liver Cancer staging system in Europe. Liver Int, 36(6):911–917. https://doi.org/10.1111/liv.13045
Kudo M, Chung H, Osaki Y, 2003. Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging score (JIS score). J Gastroenterol, 38(3):207–215. https://doi.org/10.1007/s005350300038
Kulik L, El-Serag HB, 2019. Epidemiology and management of hepatocellular carcinoma. Gastroenterology, 156(2):477–491.e1. https://doi.org/10.1053/j.gastro.2018.08.065
Lee YS, Seo YS, Kim JH, et al., 2018. Can more aggressive treatment improve prognosis in patients with hepatocellular carcinoma? A direct comparison of the Hong Kong Liver Cancer and Barcelona Clinic Liver Cancer algorithms. Gut Liver, 12(1):94–101. https://doi.org/10.5009/gnl17040
Leung TWT, Tang AMY, Zee B, et al., 2002. Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients. Cancer, 94(6):1760–1769. https://doi.org/10.1002/cncr.10384
Liao MJ, Sun JR, Zhang QF, et al., 2021. A novel post-operative ALRI model accurately predicts clinical outcomes of resected hepatocellular carcinoma patients. Front Oncol, 11: 665497. https://doi.org/10.3389/fonc.2021.665497
Marrero JA, Kulik LM, Sirlin CB, et al., 2018. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology, 68(2):723–750. https://doi.org/10.1002/hep.29913
Mazzaferro V, Sposito C, Zhou J, et al., 2018. Metroticket 2.0 model for analysis of competing risks of death after liver transplantation for hepatocellular carcinoma. Gastroenterology, 154(1):128–139. https://doi.org/10.1053/j.gastro.2017.09.025
Moris D, Shaw BI, McElroy L, et al., 2020. Using hepatocellular carcinoma tumor burden score to stratify prognosis after liver transplantation. Cancers (Basel), 12(11):3372. https://doi.org/10.3390/cancers12113372
Nanashima A, Sumida Y, Morino S, et al., 2004. The Japanese integrated staging score using liver damage grade for hepatocellular carcinoma in patients after hepatectomy. Eur J Surg Oncol, 30(7):765–770. https://doi.org/10.1016/j.ejso.2004.05.003
Nanashima A, Sumida Y, Abo T, et al., 2006. Modified Japan Integrated Staging is currently the best available staging system for hepatocellular carcinoma patients who have undergone hepatectomy. J Gastroenterol, 41(3):250–256. https://doi.org/10.1007/s00535-005-1751-4
Noordzij M, Leffondré K, van Stralen KJ, et al., 2013. When do we need competing risks methods for survival analysis in nephrology? Nephrol Dial Transplant, 28(11): 2670–2677. https://doi.org/10.1093/ndt/gft355
Okuda K, Obata H, Nakajima Y, et al., 1984. Prognosis of primary hepatocellular carcinoma. Hepatology, 4(S1):3S–6S. https://doi.org/10.1002/hep.1840040703
Parikh ND, Singal AG, 2016. The ITA.LI.CA staging system: a novel staging system for hepatocellular carcinoma. PLoS Med, 13(4):e1002005. https://doi.org/10.1371/journal.pmed.1002005
Park S, Choi S, Cho YA, et al., 2020. Evaluation of the American Joint Committee on Cancer (AJCC) 8th edition staging system for hepatocellular carcinoma in 1008 patients with curative resection. Cancer Res Treat, 52(4): 1145–1152. https://doi.org/10.4143/crt.2020.208
Qin W, Wang L, Hu BY, et al., 2019. A novel score predicts HBV-related hepatocellular carcinoma recurrence after hepatectomy: a retrospective multicenter study. J Gastrointest Surg, 23(5):922–932. https://doi.org/10.1007/s11605-018-4037-x
Reig M, Forner A, Rimola J, et al., 2022. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol, 76(3):681–693. https://doi.org/10.1016/j.jhep.2021.11.018
Selby LKF, Tay RXY, Woon WWL, et al., 2017. Validity of the Barcelona Clinic Liver Cancer and Hong Kong Liver Cancer staging systems for hepatocellular carcinoma in Singapore. J Hepatobiliary Pancreat Sci, 24(3): 143–152. https://doi.org/10.1002/jhbp.423
Shindoh J, Andreou A, Aloia TA, et al., 2013. Microvascular invasion does not predict long-term survival in hepatocellular carcinoma up to 2 cm: reappraisal of the staging system for solitary tumors. Ann Surg Oncol, 20(4):1223–1229. https://doi.org/10.1245/s10434-012-2739-y
Sinn DH, Cho JY, Gwak GY, et al., 2015. Different survival of Barcelona Clinic Liver Cancer stage C hepatocellular carcinoma patients by the extent of portal vein invasion and the type of extrahepatic spread. PLoS ONE, 10(4): e0124434. https://doi.org/10.1371/journal.pone.0124434
Su LH, Zhou T, Zhang ZL, et al., 2016. Optimal staging system for predicting the prognosis of patients with hepatocellular carcinoma in China: a retrospective study. BMC Cancer, 16:1245. https://doi.org/10.1186/s12885-016-2420-0
Tabrizian P, Jibara G, Shrager B, et al., 2015. Recurrence of hepatocellular cancer after resection: patterns, treatments, and prognosis. Ann Surg, 261(5):947–955. https://doi.org/10.1097/SLA.0000000000000710
Tellapuri S, Sutphin PD, Beg MS, et al., 2018. Staging systems of hepatocellular carcinoma: a review. Indian J Gastroenterol, 37(6):481–491. https://doi.org/10.1007/s12664-018-0915-0
Verna EC, Patel YA, Aggarwal A, et al., 2020. Liver transplantation for hepatocellular carcinoma: management after the transplant. Am J Transplant, 20(2):333–347. https://doi.org/10.1111/ajt.15697
Vitale A, Farinati F, Noaro G, et al., 2018. Restaging patients with hepatocellular carcinoma before additional treatment decisions: a multicenter cohort study. Hepatology, 68(4): 1232–1244. https://doi.org/10.1002/hep.30185
Wada H, Eguchi H, Noda T, et al., 2016. Selection criteria for hepatic resection in intermediate-stage (BCLC stage B) multiple hepatocellular carcinoma. Surgery, 160(5): 1227–1235. https://doi.org/10.1016/j.surg.2016.05.023
Wang CW, He W, Yuan YC, et al., 2020. Comparison of the prognostic value of inflammation-based scores in early recurrent hepatocellular carcinoma after hepatectomy. Liver Int, 40(1):229–239. https://doi.org/10.1111/liv.14281
Wang HB, Lu ZM, Zhao XX, 2019. Tumorigenesis, diagnosis, and therapeutic potential of exosomes in liver cancer. J Hematol Oncol, 12:133. https://doi.org/10.1186/s13045-019-0806-6
Wang L, Xian YT, Yang ZQ, 2019. Comparison of 10 prognostic staging systems in patients with advanced hepatocellular carcinoma. J BUON, 24(1):150–157.
Xu LL, Li L, Wang P, et al., 2019. Novel prognostic nomograms for hepatocellular carcinoma patients with microvascular invasion: experience from a single center. Gut Liver, 13(6):669–682. https://doi.org/10.5009/gnl18489
Xu W, Li RN, Liu F, 2020. Novel prognostic nomograms for predicting early and late recurrence of hepatocellular carcinoma after curative hepatectomy. Cancer Manag Res, 12:1693–1712. https://doi.org/10.2147/CMAR.S241959
Yan XP, Fu X, Cai C, et al., 2015. Validation of models in patients with hepatocellular carcinoma: comparison of Hong Kong Liver Cancer with Barcelona Clinic Liver Cancer staging system in a Chinese cohort. Eur J Gastroenterol Hepatol, 27(10):1180–1186. https://doi.org/10.1097/MEG.0000000000000418
Yau T, Tang VYF, Yao TJ, et al., 2014. Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma. Gastroenterology, 146(7):1691–1700.e3. https://doi.org/10.1053/j.gastro.2014.02.032
Zhang GQ, Li RF, Zhao XY, et al., 2018. Validation of the American Joint Committee on Cancer eighth edition staging system in patients undergoing hepatectomy for hepatocellular carcinoma: a US population-based study. J Surg Res, 222:55–68. https://doi.org/10.1016/j.jss.2017.09.044
Zhang XP, Wang K, Wei XB, et al., 2019. An Eastern Hepatobiliary Surgery Hospital microvascular invasion scoring system in predicting prognosis of patients with hepatocellular carcinoma and microvascular invasion after R0 liver resection: a large-scale, multicenter study. Oncologist, 24(12):e1476–e1488. https://doi.org/10.1634/theoncologist.2018-0868
Zhang ZH, Shen SL, Chen B, et al., 2019. Hepatic resection provides survival benefit for selected intermediate-stage (BCLC-B) hepatocellular carcinoma patients. Cancer Res Treat, 51(1):65–72. https://doi.org/10.4143/crt.2018.038
Zhong JH, Ke Y, Gong WF, et al., 2014. Hepatic resection associated with good survival for selected patients with intermediate and advanced-stage hepatocellular carcinoma. Ann Surg, 260(2):329–340. https://doi.org/10.1097/SLA.0000000000000236
Zhou J, Sun HC, Wang Z, et al., 2020. Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition). Liver Cancer, 9(6):682–720. https://doi.org/10.1159/000509424
Acknowledgments
This research was supported by the Guangxi Scholarship Fund of Guangxi Education Department, the Guangxi Medical University Training Program for Distinguished Young Scholars, the Advanced Innovation Teams and Xinghu Scholars Program of Guangxi Medical University, the Guangxi Medical and Health Key Discipline Construction Project, and the Science and Technology Plan Project of Qingxiu District, Nanning (Nos. 2020037, 2020038, 2021007, 2021010, and 2021012), China.
Author information
Authors and Affiliations
Corresponding author
Additional information
Author contributions
Ziqin HE and Jiazhou YE drafted and revised the manuscript. Xiaomin SHE, Ziyu LIU, Xing GAO, and Lu LU were responsible for the topics, final editing, and preparation of the manuscript for submission. Julu HUANG, Cheng LU, Yan LIN, and Rong LIANG critically revised the manuscript. All authors have read and approved the final manuscript.
Compliance with ethics guidelines
Ziqin HE, Xiaomin SHE, Ziyu LIU, Xing GAO, Lu LU, Julu HUANG, Cheng LU, Yan LIN, Rong LIANG, and Jiazhou YE declare that they have no conflict of interest.
This review does not contain any studies with human or animal subjects performed by any of the authors.
Rights and permissions
About this article
Cite this article
He, Z., She, X., Liu, Z. et al. Advances in post-operative prognostic models for hepatocellular carcinoma. J. Zhejiang Univ. Sci. B 24, 191–206 (2023). https://doi.org/10.1631/jzus.B2200067
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1631/jzus.B2200067
Key words
- Hepatocellular carcinoma
- Clinical stage
- Tumor-Node-Metastasis (TNM)
- Barcelona Clinic Liver Cancer (BCLC)
- Nomogram